Private Placement Calendar

Upcoming Closings

By June 30, 2018

STRONGBRIDGE BIOPHARMA PLC:

• $50 million six-year 12.5% senior credit facility;

• The company borrowed $40 million on July 17, 2017 and will have access to an additional $10 million by June 30, 2018 upon achievement of certain milestones;

• Credit facility may be prepaid;

• Deal includes seven-year warrants issued to the investor for 394,289 ordinary shares, each exercisable at $7.37;

• CRG LP is the investor;

• Concurrent with the first tranche, CRG also purchased $3 million of ordinary shares at $6.98 per share;

• Proceeds will be used to retire existing debt facility and for general corporate purposes and working capital;

• Strongbridge is a Trevose, Pa., biopharmaceutical company.

June

TABCORP HOLDINGS LTD.:

• $1.4 billion of notes in six tranches, comprised of $105 million of eight-year notes; $450 million of 10-year notes; $520 million of 12-year notes; $175 million of 15-year notes; A$97.5 million, or $75 million, of 17-year notes and A$97.5 million, or $75 million, of 18-year notes;

• Proceeds will be used to repay in full the company’s A$1.8 billion bridge financing facility and to repay existing bank debt;

• Tabcorp is a Melbourne, Australia-based leisure and entertainment services company operating in three segments: casinos, wagering and gaming.

By Aug. 14, 2019

OPTINOSE INC., OPTINOSE US, INC. AND OPTINOSE AS:

• $100 million of floating-rate senior secured notes due June 29, 2023, with $50 million of the notes issued by OptiNose US, Inc. and $50 million of the notes issued by OptiNose AS; of the notes, $25 million was issued by OptiNose US, Inc. and $50 million was issued by OptiNose AS on Dec. 29 and the remaining $25 million to be issued by OptiNose US, Inc. between April 1, 2019 and Aug. 14, 2019;

• Notes bear interest at Libor plus 900 basis points with a Libor floor of 1%;

• Proceeds will be used to provide ongoing working capital for the company to support the launch and commercialization of Xhance (fluticasone propionate) nasal spray, 93 mcg, as well as for general corporate purposes;

• OptiNose is a specialty pharmaceutical company based in Yardley, Pa.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.